Quick Answer
Cue Biopharma, Inc. reported Research And Development Expense of $37.74 million for the year ending 2025.
- Cue Biopharma, Inc. showed an increase of +4.0% in Research And Development Expense from 2024 to 2025.
- This data is from Cue Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $2.46 million | Q2 2017: $3.42 million | Q3 2017: $4.00 million | Q1 2018: $5.82 million | Q2 2018: $5.41 million | Q3 2018: $10.31 million | Q1 2019: $8.35 million | Q2 2019: $6.87 million | Q3 2019: $5.30 million | Q1 2020: $9.91 million | Q2 2020: $8.12 million | Q3 2020: $7.52 million | Q1 2021: $9.82 million | Q2 2021: $8.76 million | Q3 2021: $11.29 million | Q1 2022: $10.08 million | Q2 2022: $9.59 million | Q3 2022: $7.57 million | Q1 2023: $9.39 million | Q2 2023: $10.65 million | Q3 2023: $9.87 million | Q1 2024: $10.20 million | Q2 2024: $9.53 million | Q3 2024: $9.38 million | Q1 2025: $8.55 million | Q2 2025: $7.91 million | Q3 2025: $4.75 million.
- Over the full 9 years of available data (2017 to 2025), Cue Biopharma, Inc.'s Research And Development Expense has grown by 99.7%.
- Historical annual values: Fiscal year 2025: $37.74 million | Fiscal year 2024: $36.30 million | Fiscal year 2023: $40.80 million | Fiscal year 2022: $38.58 million | Fiscal year 2021: $41.35 million | Fiscal year 2020: $33.55 million | Fiscal year 2019: $27.49 million | Fiscal year 2018: $28.54 million | Fiscal year 2017: $18.90 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: